Company / Financials
Amphstar Pharmaceuticals, Inc. Financials
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$719.9M
FY2025 · -1.7% YoY
Net Income
$98.1M
FY2025 · -38.5% YoY
Profit Margin
13.6%
FY2025 · net income / revenue
ROE
12.4%
FY2025 · return on equity
Total Assets
$1.6B
FY2025
Total Debt
$619.7M
0.79x debt/equity
Equity
$788.8M
FY2025
ROA
6.0%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Strong profit margin: 21.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$719.9M-1.7% YoYNet Income HistoryProfit after all expenses and taxes$98.1M-38.5% YoYGross Profit HistoryRevenue minus cost of goods sold$356.1M-4.8% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$363.8M+1.6% YoYOperating Income HistoryProfit from core business operations before interest and taxes$140.4M-31.7% YoYSG&A Expense HistorySelling, general, and administrative expenses$85.9M+51.5% YoYR&D Expense HistoryResearch and development spending$85.8M+16.1% YoYInterest Expense HistoryCost of borrowing and debt obligations$27.2MIncome Tax HistoryTotal income tax expense$25.5M-14.0% YoYEPS (Basic) HistoryBasic earnings per share$2.85+51.6% YoY